Phase 3 Chronic Rhinosinusitis Trial, Terminated NCT02285283 Sponsor: The University of Texas Health Science Center, Houston Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial (NCT02285283) enrolled 58 people in total — 29 received a placebo (a dummy treatment with no active ingredient) and 29 received itraconazole, an antifungal medicine. The trial was measuring whether nasal polyps (small, non-cancerous growths inside the nose) came back after treatment to the point where further intervention was needed. Not everyone finished the study — 25 of the 29 placebo participants and 20 of the 29 itraconazole participants completed it. The reported data shows that, for the primary outcome — the number of people whose nasal polyps returned and required further intervention — 3 out of 29 participants in the placebo group and 4 out of 29 participants in the itraconazole group reached that point. For the secondary outcome, which tracked the number of participants who experienced adverse events (unwanted side effects or health problems) while taking the medication or placebo, the reported data shows zero participants in either group recorded an adverse event during that period. It is worth noting that 9 participants in the itraconazole group did not complete the study, compared with 4 in the placebo group, though the reasons for this were not detailed in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Phase 3 Chronic Rhinosinusitis Trial, Terminated

NCT02285283
Terminated Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with chronic rhinosinusitis (long-term sinus inflammation) with nasal polyps, and your doctor has recommended sinus surgery as part of your treatment

Who may not be able to join:

  • You have cystic fibrosis
  • You have a condition where taking aspirin makes your breathing problems worse (sometimes called aspirin-sensitive asthma or similar)
  • You have a chronic (long-term) illness that is not well-controlled or is unstable, such as uncontrolled diabetes
  • You currently have cancer or have had cancer in the past
  • You are HIV positive
  • You have a history of liver or kidney disease
  • You have a history of any condition that affects how your immune system works
  • You are pregnant
  • You have an allergy to a type of antifungal medication called triazole antifungals (confirm with trial site if you are unsure whether your medication falls into this category)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Terminated
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
1 November 2014
Est. completion
15 May 2019

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Participants With Recurrence of Nasal Polyps Requiring Intervention

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov